LCGPA Signs Deals to Localize Biopharma Production

The Local Content and Government Procurement Authority (LCGPA) has signed three agreements with private-sector companies at the Riyadh Global Medical Biotechnology Summit 2026 to support the localization of biopharmaceutical manufacturing. The agreements, announced on September 16, 2026, cover the local production of three biopharmaceuticals: semaglutide, aflibercept, and ustekinumab. They also provide for the transfer of knowledge, expertise, and advanced technologies to Saudi Arabia, marking a significant step in the Kingdom’s efforts to build a self-sufficient and innovative healthcare sector.

Context and Background

The Riyadh Global Medical Biotechnology Summit 2026 serves as a premier platform for advancing biotechnology and pharmaceutical innovation in the region. The LCGPA, a key government entity responsible for enhancing local content in public procurement, has been instrumental in driving initiatives that align with Saudi Vision 2030, which aims to diversify the economy and reduce reliance on oil. By partnering with private-sector companies, the LCGPA seeks to localize critical industries, including biopharmaceuticals, to strengthen national capabilities and supply chain resilience. This move follows a series of strategic investments in healthcare and biotechnology, positioning Saudi Arabia as a leader in medical innovation.

Key Details

According to the LCGPA spokesperson Abdulrahman Al-Sagheer, the agreements are expected to contribute an estimated SAR4.4 billion to GDP and create more than 800 jobs. The three biopharmaceuticals—semaglutide (used for diabetes and obesity), aflibercept (for eye disorders), and ustekinumab (for autoimmune diseases)—will be produced locally, reducing import dependence and ensuring timely access to essential medicines. The agreements also include provisions for technology transfer, which will enhance the skills of Saudi professionals and foster a knowledge-based economy. These collaborations are part of broader efforts to localize the pharmaceutical sector, with the LCGPA working closely with international and domestic partners to achieve self-sufficiency in critical medical supplies.

Implications and Impact

The localization of biopharmaceutical production is set to have far-reaching implications for Saudi Arabia’s healthcare sector and economy. By manufacturing these treatments domestically, the Kingdom will not only secure its supply of vital medicines but also stimulate economic growth through job creation and industrial development. This initiative aligns with the goals of Vision 2030 by promoting innovation, enhancing local content, and attracting foreign investment. Furthermore, it positions Saudi Arabia as a regional hub for biotechnology, potentially exporting these products to neighboring markets. The transfer of advanced technologies will also spur research and development, fostering a culture of scientific excellence and collaboration between local and international entities.

Vision 2030 Alignment

This development is a direct reflection of Saudi Vision 2030’s objectives to diversify the economy, improve healthcare outcomes, and build a sustainable, knowledge-driven society. By localizing biopharmaceutical production, the Kingdom is not only strengthening its industrial base but also reinforcing its commitment to innovation and self-reliance. As Saudi Arabia continues to invest in strategic sectors, such initiatives will play a pivotal role in shaping a prosperous future, ensuring that the nation remains at the forefront of global advancements in healthcare and biotechnology.

20 Questions

Q1. What is the LCGPA?

A1. The Local Content and Government Procurement Authority is a Saudi government entity responsible for enhancing local content in public procurement and supporting economic diversification.

Q2. What agreements were signed by the LCGPA?

A2. The LCGPA signed three agreements with private-sector companies to localize the production of semaglutide, aflibercept, and ustekinumab.

Q3. Where were these agreements signed?

A3. The agreements were signed at the Riyadh Global Medical Biotechnology Summit 2026, a key event for advancing biotechnology in the region.

Q4. What is the expected economic contribution of these agreements?

A4. The agreements are expected to contribute an estimated SAR4.4 billion to Saudi Arabia’s GDP, supporting economic growth and diversification.

Q5. How many jobs will be created?

A5. More than 800 jobs are expected to be created, providing opportunities for Saudi professionals in the biopharmaceutical sector.

Q6. What is semaglutide used for?

A6. Semaglutide is a medication used to treat type 2 diabetes and obesity, and its local production will enhance access for patients in Saudi Arabia.

Q7. What is aflibercept used for?

A7. Aflibercept is used to treat eye disorders such as macular degeneration, and local production will ensure a steady supply.

Q8. What is ustekinumab used for?

A8. Ustekinumab is used to treat autoimmune diseases like psoriasis and Crohn’s disease, and local manufacturing will improve patient access.

Q9. What does the transfer of knowledge and expertise entail?

A9. It involves sharing advanced technologies and skills with Saudi Arabia to build local capabilities and foster a knowledge-based economy.

Q10. How does this align with Saudi Vision 2030?

A10. It supports economic diversification, healthcare improvement, and local content development, all key pillars of Vision 2030.

Q11. Who is Abdulrahman Al-Sagheer?

A11. Abdulrahman Al-Sagheer is the spokesperson for the LCGPA, who announced the expected economic benefits of the agreements.

Q12. What is the significance of localizing biopharmaceutical production?

A12. It reduces dependence on imports, ensures supply chain resilience, and positions Saudi Arabia as a regional hub for biotechnology.

Q13. Which private-sector companies are involved?

A13. The specific companies were not named in the announcement, but they are private-sector entities partnering with the LCGPA.

Q14. How will these agreements impact the Saudi healthcare sector?

A14. They will enhance access to essential medicines, create jobs, and stimulate innovation in the healthcare and biotechnology sectors.

Q15. What is the Riyadh Global Medical Biotechnology Summit?

A15. It is a premier event that brings together experts and stakeholders to advance biotechnology and pharmaceutical innovation in Saudi Arabia.

Q16. Will these products be exported?

A16. While the primary focus is on local supply, increased production capacity could potentially lead to exports in the future.

Q17. How does this initiative support national capabilities?

A17. By transferring technology and expertise, it builds the skills of Saudi professionals and strengthens local industries.

Q18. What role does the LCGPA play in Vision 2030?

A18. The LCGPA drives local content development, which is essential for economic diversification and sustainable growth under Vision 2030.

Q19. What are the next steps following these agreements?

A19. The agreements will be implemented with the private-sector partners, focusing on establishing local production facilities and technology transfer.

Q20. How will this impact Saudi Arabia’s global standing?

A20. It will enhance the Kingdom’s reputation as a leader in biotechnology and healthcare innovation, attracting further investment and collaboration.

---